Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 154 participants.

Also called NCT02426294

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02426294
Other papers using this trial's data
  • Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study Diabetes & metabolism journal, 2020-02 DOI, PubMed 31339011, PMC7043969 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02426294. Randomized; no masking; primary purpose treatment. Start 2015-02 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Glimepiride
Lead sponsor
Pusan National University Hospital (class: other)

Record details

Record id
cardio:ct-nct02426294
Content hash
43b84fe6d8d5979bb84c72c389be1d21d4f796d13dbfe33dae6c002fad8abc60